Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC [Phase 3]
Phase III study evaluating two regimens of abiraterone acetate in metastatic castration-resistant prostate cancer is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial investigating cyclophosphamide plus dexamethasone for metastatic castration-resistant prostate cancer; the study is c…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Investigation of PSMA PET/CT as an Imaging Biomarker in Solid Tumors [NA]
This clinical trial update notes the completion of a study evaluating PSMA PET/CT as an imaging biomarker in metastatic castration-resistant…
-
CLINICAL_TRIALS research · 2024-12-31Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 3]
Phase III multicenter randomized trial evaluating Fuzuloparib in combination with Abiraterone acetate and prednisone versus placebo with Abi…
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging [Phase 3]
Phase 3 trial evaluating darolutamide with or without radiation therapy for metastatic castration-resistant prostate cancer; currently recru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-11Clinical Trial Update: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Ga-68-NGUL and Lu-177-DGUL in metastatic castration-resistant prostate cancer is currently active but …
-
CLINICAL_TRIALS research · 2024-12-06Clinical Trial Update: Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
A prospective observational KiRi-Trial investigates kidney function and risk factors in patients with metastatic castration-resistant prosta…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X) [Phase 2]
A Phase 2 clinical trial (PCS X) is investigating management of oligoprogressive metastatic castration-resistant prostate cancer, with recru…
-
CLINICAL_TRIALS research · 2024-12-04Clinical Trial Update: Management of Castration-Resistant Prostate Cancer with Oligometastases [Phase 2, Phase 3]
This document reports an ongoing Phase 2/Phase 3 clinical trial evaluating management of castration-resistant prostate cancer with oligometa…
-
CLINICAL_TRIALS research · 2024-11-27Clinical Trial Update: 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer [Phase 4]
A Phase 4 trial evaluating whether 18F-Fluciclovine PET/CT can predict outcomes of 177Lu-PSMA-617 therapy in prostate cancer patients. The s…
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC [Phase 2]
Phase II randomized trial comparing patient-specific adaptive dosing versus continuous dosing of Abiraterone acetate or Enzalutamide for met…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors [Phase 1]
Phase 1 study evaluating XL092 as a single-agent and combination therapy for solid tumors, including renal cell carcinoma, hormone receptor-…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating RC48 monotherapy or RC48 in combination with Envafolimab for metastatic castration-resistant pr…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
European observational study evaluating enzalutamide in metastatic castration-resistant prostate cancer has completed. The study's findings …
-
CLINICAL_TRIALS research · 2024-09-27Clinical Trial Update: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer [Phase 2]
This update describes a Phase 2 trial evaluating sequencing of Radium-223 and Docetaxel for symptomatic bone-only metastatic castration-resi…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
This entry notes a recruiting clinical trial evaluating circulating tumor DNA as a biomarker to assess and predict the efficacy of PARP inhi…
-
CLINICAL_TRIALS research · 2024-09-05Clinical Trial Update: Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer [Phase 3]
A Phase 3 trial evaluating metastasis-directed therapy for oligoprogressive disease in men with castration-resistant prostate cancer is curr…
-
CLINICAL_TRIALS research · 2024-08-20Clinical Trial Update: ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors [Phase 2]
Phase 2 study ARTEMIS-003 evaluating HS-20093 in metastatic castration-resistant prostate cancer and advanced solid tumors is currently recr…
-
CLINICAL_TRIALS research · 2024-08-14Clinical Trial Update: Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study [Phase 1]
A Phase 1 dose-escalation study evaluating 161Tb-SibuDAB, a new PSMA-targeted radioligand therapy, in metastatic castration-resistant prosta…
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） [EARLY_Phase 1]
An early Phase 1 trial evaluating [177Lu]Lu-PSMA-137 for metastatic castration-resistant prostate cancer, with not-yet-recruiting status and…
-
CLINICAL_TRIALS research · 2024-07-31Clinical Trial Update: Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
A clinical trial evaluating organoid-based drug sensitivity screening to guide treatment for metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2024-07-15Clinical Trial Update: Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer. [Phase 2]
Phase 2 clinical trial update evaluating Abiraterone Acetate in combination with Darxicilib or Dalpicilib for metastatic castration-resistan…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer [NA]
Update on a clinical trial evaluating 177Lu-PSMA-EB-01 in patients with metastatic castration-resistant prostate cancer; the study is curren…
-
CLINICAL_TRIALS research · 2024-06-27Clinical Trial Update: Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC [Phase 2]
Phase 2 clinical trial evaluating docetaxel or cabazitaxel with or without darolutamide in metastatic castration-resistant prostate cancer; …
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS) [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with carboplatin and cabazitaxel for aggressive metastatic castration-resis…